Tcr2 Therapeutics EBIT

Tcr2 Therapeutics posts a EBIT of $-170M as of March 2023. That compares with $-110M in the prior-year period — down 54.6% year over year. That is below the Healthcare sector average of $23B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Tcr2 Therapeutics's EBIT was $-110M. The latest reading is $-170M — a 54.6% year-over-year decrease (period ending March 2023). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a EBIT near $23B is typical. Tcr2 Therapeutics's $-170M is lower that level. That is roughly 100.7% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

EBIT is one piece of Tcr2 Therapeutics's financial statement story. At $-170M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for TCRR's EBIT usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $23B), and (3) consistency with growth and profitability. This page covers the first two; Tcr2 Therapeutics's other metric pages and overview cover the third.